Faculty

Faculty

Sarah Karpen

MPAS, PA-C

Moores Cancer Center, University of California San Diego Health, San Diego, California

APP Supervisor Medical Oncology, Division of Gynecologic Oncology

Faculty

J Alejandro Rauh-Hain

MD, MPH

The University of Texas MD Anderson Cancer Center Houston, Texas

Associate Professor, Tenure Track Deputy Division Head for Clinical Research, Division of Surgery Dept of Gynecologic Oncology and Reproductive Medicine Dept of Health Services Research

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

Moderator

Dana M Chase

MD

David Geffen School of Medicine at UCLA, Los Angeles, California

Professor, Division of Gynecologic Oncology

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

• Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
• Similarities and differences among the currently available anti-PD-1/PD-L1 antibodies for EC, such as dostarlimab, pembrolizumab and durvalumab
• Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
• Frequency of potential biomarkers of response to immune checkpoint inhibitors in EC (eg, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, POLE mutations); optimal approach to biomarker assessment for patients with newly diagnosed disease

MODULE 2: First-Line Therapy for Advanced or Recurrent EC

• Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
• Impact of MSI/MMR status on outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
• Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

MODULE 3: Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

• Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
• Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by dostarlimab/niraparib maintenance compared to carboplatin/paclitaxel alone in advanced or recurrent EC
• Published efficacy and safety results with durvalumab in combination with chemotherapy followed by durvalumab and olaparib maintenance for patients with newly diagnosed advanced or recurrent EC
• Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

MODULE 4: Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

• Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies in advanced EC
• Recommended monitoring and management approaches for immune-related and other AEs with immune checkpoint inhibitors
• Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic partners (eg, chemotherapy, PARP inhibitors) when these agents are administered in combination
• Role of rechallenge in treatment for patients for whom immune checkpoint inhibitor therapy has been held due to immune-mediated toxicity
• Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

MODULE 5: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

• Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
• Long-term findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC with disease progression after prior systemic therapy
• Optimal integration of lenvatinib/pembrolizumab into EC management algorithms
• Utility of lenvatinib/pembrolizumab among patients who have experienced disease progression on up-front chemoimmunotherapy

MODULE 6: Toxicities with Lenvatinib/Pembrolizumab

• Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab (eg, hypertension, gastrointestinal issues, weight loss, hand-foot syndrome)
• Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
• Initial dosing and dose-modification strategies for lenvatinib/pembrolizumab in EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
• Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab among patients receiving the combination

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC).
• Appreciate available clinical research findings with the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
• Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
• Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents/regimens.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Shaver and Dr Rauh-Hain have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Karpen — Speakers Bureaus: Amgen Inc.

MODERATOR — Dr Chase — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; Consulting Agreements: AbbVie Inc, GSK; Contracted Research: GSK, Merck; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; Nonrelevant Financial Relationships: NRG Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Bradley J Monk

MD

Florida Cancer Specialists & Research Institute, West Palm Beach, Florida

Medical Director, Late-Phase Research Program

University of Central Florida College of Medicine

Professor

GOG Foundation, West Palm Beach, Florida

Vice President and Member, Board of Directors

GOG Partners, West Palm Beach, Florida

Co-Director

Faculty

Kathryn M Schlenker

MSN, WHNP-BC, AGNP-C

The University of Alabama at Birmingham, Birmingham, Alabama

Nurse Practitioner, Division of Gynecologic Oncology

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

Moderator

David M O'Malley

MD

The Ohio State University and The James Comprehensive Cancer Center, Columbus, Ohio

Director and Professor, Division of Gynecologic Oncology in Obstetrics and Gynecology, John G Boutselis Chair in Gynecologic Oncology

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Importance of Genetic Testing in the Care of Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

• Similarities and differences between germline and somatic genetic mutations
• Incidence and clinical significance of BRCA mutations and other germline or somatic alterations (eg, PALB2, ATM, RAD51C/D) in ovarian cancer
• Current roles of next-generation sequencing and germline sequencing for advanced ovarian cancer; similarities and differences among available genetic testing platforms
• Purpose and potential benefits of genetic counseling after a diagnosis of ovarian cancer

MODULE 2: Role of PARP Inhibitors for Advanced Ovarian Cancer

• Mechanism of antitumor activity of PARP inhibitors, and rationale for their use as maintenance therapy for patients with newly diagnosed advanced ovarian cancer
• Long-term findings from Phase III studies with olaparib, olaparib/bevacizumab and niraparib maintenance for newly diagnosed ovarian cancer
• Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab or niraparib maintenance
• Current clinical utility, if any, of PARP inhibitors for relapsed/refractory ovarian cancer, including among patients who have experienced disease progression on or after prior PARP inhibitor therapy

MODULE 3: Side Effects and Other Practical Considerations with PARP Inhibitors

• Initial dosing and appropriate dose-modification strategies for approved PARP inhibitors
• Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with ovarian cancer
• Optimal monitoring and management paradigms for common PARP inhibitor-related toxicities
• Long-term risk of acute myeloid leukemia/myelodysplastic syndromes with PARP inhibitor therapy
• Importance of adherence among patients receiving long-term oral medications, including PARP inhibitors; strategies to encourage and assess adherence

MODULE 4: Current and Future Role of Mirvetuximab Soravtansine in Ovarian Cancer Treatment

• Frequency of and scientific rationale for targeting folate receptor alpha (FRα) in ovarian cancer
• Mechanism of action and structural components of mirvetuximab soravtansine
• Published research findings with mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer
• FDA approval of mirvetuximab soravtansine for FRα-high, platinum-resistant ovarian cancer; implications for biomarker assessment and current management
• Early findings with mirvetuximab soravtansine for FRα-high, platinum-sensitive advanced ovarian cancer; ongoing evaluation and potential utility in this setting

MODULE 5: Toxicities Associated with Mirvetuximab Soravtansine

• Pathophysiology and incidence of ocular toxicities observed with mirvetuximab soravtansine
• Monitoring and management techniques for mirvetuximab soravtansine-related ocular events
• Importance of collaboration with eye care specialists for patients receiving mirvetuximab soravtansine
• Spectrum, frequency, severity and timing of other common toxicities reported with mirvetuximab soravtansine; optimal management approaches

MODULE 6: Other Approved and Investigational Antibody-Drug Conjugates for Ovarian Cancer

• Frequency of HER2 expression in advanced ovarian cancer; optimal timing of and approach to testing
• FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors; implications for ovarian cancer management
• Biological rationale for targeting CDH6 for ovarian cancer; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
• Early research findings with and ongoing evaluation of R-DXd for heavily pretreated platinum-resistant advanced ovarian cancer

MODULE 7: Current Role of Relacorilant for Advanced OC

• Incidence and clinical relevance of glucocorticoid receptor (GR) overexpression in ovarian cancer
• Mechanism of action of the selective GR modulator relacorilant; rationale for combining relacorilant with chemotherapy for advanced ovarian cancer
• Published efficacy and safety findings with relacorilant in combination with nab paclitaxel versus nab paclitaxel alone for platinum-resistant advanced ovarian cancer
• Recent FDA approval of relacorilant in combination with nab paclitaxel for platinum-resistant advanced ovarian cancer, and integration into current clinical algorithms

MODULE 8: Tolerability Considerations with Relacorilant/Nab Paclitaxel

• Rationale for nab paclitaxel as a therapeutic partner for relacorilant; necessity of avoiding corticosteroid use with relacorilant
• Tolerability profile of relacorilant/nab paclitaxel in published clinical trials; relative contributions of each agent in terms of toxicities
• Incidence and severity of cytopenias with relacorilant/nab paclitaxel; appropriate monitoring and management
• Rates of and strategies to manage peripheral neuropathy with relacorilant/nab paclitaxel

MODULE 9: Utility of Immune Checkpoint Inhibition for Advanced OC

• Historical outcomes documented with anti-PD-1/PD-L1 antibodies as monotherapy for advanced ovarian cancer; potential explanations for the lack of activity with these agents for ovarian cancer relative to other tumor types
• Emerging data demonstrating a progression-free survival advantage with the addition of pembrolizumab to chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer
• Impact of PD-L1 expression on overall survival in the aforementioned emerging data set; potential implications for biomarker analysis for advanced ovarian cancer
• Potential clinical role of pembrolizumab for platinum-resistant recurrent ovarian cancer

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors alone or in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and counsel appropriate individuals regarding personalized treatment recommendations.
• Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
• Understand the structural components and mechanism of action of antibody-drug conjugates (ADCs) directed at folate receptor alpha, and discuss current research findings with these agents.
• Assess available clinical research findings with immunotherapy in combination with chemotherapy for patients with platinum-resistant OC, and consider the integration of this therapeutic strategy into care for individuals with advanced disease.
• Review Phase III findings with selective glucocorticoid receptor modulators with chemotherapy for patients with platinum-resistant OC, and consider the current role of this combination in this treatment setting.
• Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.
• Recall the biological rationale for the evaluation of other ADCs with alternative targets (eg, HER2, CDH6, TROP2) for OC, and consider the current and future role of these agents.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OvarianCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Schlenker and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Monk — Consulting Agreements: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

MODERATOR — Dr O’Malley — Consulting Agreements — Personal Fees (Consult and/or Advisory Boards): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; Contracted Research (Institution Received Funds for Research): AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; Data and Safety Monitoring Boards/Committees: Frantz Viral Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.